Form 4: LifeCore Biomedical CFO Vests Performance-Based Stock Units, Sells Shares for Tax Obligations

LifeCore Biomedical's Chief Financial Officer, Ryan David Lake, acquired 75,000 shares of common stock through the vesting of performance-based restricted stock units and subsequently disposed of 32,806 shares to cover tax withholding obligations.

Summary

• Ryan David Lake, Chief Financial Officer of LIFECORE BIOMEDICAL, INC. (LFCR), reported transactions on July 8, 2025.
• Lake acquired 75,000 shares of common stock due to the vesting of performance-based restricted stock units (RSUs).
• The vesting of these RSUs was triggered by the Issuer's achievement of a specific stock price milestone.
• Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the achievement of certain stock prices.
• Concurrently, 32,806 shares of common stock were disposed of at a price of $8.19 per share.
• This disposition was to satisfy applicable tax withholding obligations related to the vesting and settlement of the performance stock unit award.
• Following these transactions, Ryan David Lake directly beneficially owns 359,623 shares of common stock.
• Additionally, Lake directly beneficially owns 600,000 performance-based restricted stock units.
• The remaining 600,000 performance-based restricted stock units have an expiration date of September 3, 2029.

Sentiment

Score: 7

Explanation: The vesting of performance-based RSUs is a positive indicator that the company met a stock price milestone, reflecting good performance. While shares were sold for taxes, this is a standard practice and does not detract from the underlying positive performance trigger.

Positives

• The vesting of 75,000 performance-based restricted stock units indicates that LifeCore Biomedical achieved a specific stock price milestone, demonstrating positive company performance against internal targets.
• The transaction reflects a successful outcome for the CFO's incentive compensation plan, aligning management's interests with shareholder value creation.

Negatives

• A significant portion of the vested shares (32,806 shares) were immediately sold to cover tax withholding obligations, which is a common practice but reduces the direct ownership increase from the vesting event.

Industry Context

This filing is a standard insider transaction report and does not provide broader industry context or trends. It reflects an individual executive's compensation event within the biomedical sector.

Stakeholder Impact

• Shareholders: The vesting of performance-based RSUs indicates that the company achieved a stock price milestone, which is generally positive for existing shareholders as it suggests value creation.
• Employees (specifically Ryan David Lake): The CFO benefits directly from the vesting of these equity awards, increasing their personal wealth and aligning their financial interests with the company's performance.

Key Dates

Keywords

LifeCore Biomedical, LFCR, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Chief Financial Officer, Ryan David Lake, Stock Price Milestone, Tax Withholding, Beneficial Ownership